BTIG analyst Timothy Chiang kept his Buy rating and $190 price target on Sarepta after it disclosed a complete response letter, or CRL, on golodirsen from the FDA, saying the 11% after-market stock price decline may be overdone since the "bulk" of his bull thesis on the stock is tied to the company's micro-dystrophin gene therapy program. The analyst notes that the CRL will likely push out the potential approval timing on golodirsen to 2020, and that he is removing the previously modeled $25M in in related 2019 sales from his forecasts. Chiang adds that the issues brought up by the FDA in the golodirsen are "addressable".